EGFR and non-small cell lung carcinoma: Patients with NSCLC harbouring epidermal growth factor receptor (EGFR)-activated mutations are prevalent in clinical practice and typically experience positive outcomes with EGFR tyrosine kinase inhibitors (TKIs).